Medicare Price Inflation Penalties Unlikely To Spur Greater Price Increases, Study Suggests
Results of an analysis published in JAMA could undercut arguments against legislative proposals establishing inflation penalties in Medicare.
You may also be interested in...
Price inflation rebates are the linchpin of the legislation’s Democratic support, Sen. Chuck Grassley, R-IA, argues. But to many Republicans, they sound too much like price controls.
Former senior advisor to President Trump warns that failure to reform drug pricing practices has seriously handicapped prospects for reimbursing cell and gene therapy under existing US payer programs.
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’